October, 2025
October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF
Sep 1, 2025, 07:40

JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF

Journal of the American Medical Association (JAMA) made a noteworthy post on LinkedIn:

“In patients with cardiometabolic HFpEF, semaglutide and tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.”

Read the full article here:

Article: Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction

Authors: Nils Krüger, Sebastian Schneeweiss, Kenshiro Fuse, Sofiya Matseyko, Sushama Kattinakere Sreedhara, Georg Hahn, Heribert Schunkert, Shirley V. Wang

JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF

Follow the newest insights in hematology with Hemostasis Today.